159 related articles for article (PubMed ID: 26373732)
1. Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma.
Mersch S; Riemer JC; Schlünder PM; Ghadimi MP; Ashmawy H; Möhlendick B; Topp SA; Arent T; Kröpil P; Stoecklein NH; Gabbert HE; Knoefel WT; Krieg A
Tumour Biol; 2016 Feb; 37(2):2341-51. PubMed ID: 26373732
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization.
Nishio J; Iwasaki H; Ishiguro M; Ohjimi Y; Fujita C; Ikegami H; Ariyoshi A; Naito M; Kaneko Y; Kikuchi M
Int J Oncol; 2003 Mar; 22(3):535-42. PubMed ID: 12579306
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
5. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 May; 34(3):990-997. PubMed ID: 33555519
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a novel dedifferentiated liposarcoma cell line, NDDLS-1.
Ariizumi T; Ogose A; Kawashima H; Hotta T; Li G; Xu Y; Hirose T; Endo N
Pathol Int; 2011 Aug; 61(8):461-8. PubMed ID: 21790860
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
[TBL] [Abstract][Full Text] [Related]
11. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma.
Kim YJ; Yu DB; Kim M; Choi YL
Cancer Sci; 2019 Aug; 110(8):2676-2683. PubMed ID: 31069877
[TBL] [Abstract][Full Text] [Related]
12. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.
Hwang JA; Yang HM; Hong DP; Joo SY; Choi YL; Park JH; Lazar AJ; Pollock RE; Lev D; Kim SJ
Oncotarget; 2014 Oct; 5(19):9065-78. PubMed ID: 25238053
[TBL] [Abstract][Full Text] [Related]
13. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
14. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort.
Hoffman A; Lazar AJ; Pollock RE; Lev D
Drug Resist Updat; 2011 Feb; 14(1):52-66. PubMed ID: 21169051
[TBL] [Abstract][Full Text] [Related]
15. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.
Keung EZ; Akdemir KC; Al Sannaa GA; Garnett J; Lev D; Torres KE; Lazar AJ; Rai K; Chin L
J Clin Invest; 2015 Aug; 125(8):2965-78. PubMed ID: 26193637
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiated liposarcoma with a rare presentation of disseminated intraperitoneal sarcomatosis: A case report.
Cai M; Siew CCH; Tay TKY; Tan GHC
Int J Surg Case Rep; 2019; 60():331-335. PubMed ID: 31280066
[TBL] [Abstract][Full Text] [Related]
17. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies.
Thway K; Jones RL; Noujaim J; Zaidi S; Miah AB; Fisher C
Adv Anat Pathol; 2016 Jan; 23(1):30-40. PubMed ID: 26645460
[TBL] [Abstract][Full Text] [Related]
19. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line.
Gock M; Mullins CS; Harnack C; Prall F; Ramer R; Göder A; Krämer OH; Klar E; Linnebacher M
World J Gastroenterol; 2018 Sep; 24(33):3749-3759. PubMed ID: 30197480
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal sarcomatosis versus peritoneal carcinomatosis: imaging findings at MDCT.
Oei TN; Jagannathan JP; Ramaiya N; Ros PR
AJR Am J Roentgenol; 2010 Sep; 195(3):W229-35. PubMed ID: 20729420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
